no underlying reason for buyingJust becuase the company recieved a grant (that really is not that much considering the cost of medical research; over two years salaries alone will cost about $250,000) is no reason for a jump in the SP. The company is purely speculative. It is an early stage company that is in the gutter for a reason, which is weak prospects. Its two drugs that it will try to develop for cancer and HIV are being pursued by many more well funded companies with absolutely no headway, so what is the promise for genvec?